Tenaya Therapeutics Inc

NASDAQ TNYA

Data sourced from

and

Download Data

Tenaya Therapeutics Inc EBIT to Total Assets Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -38.41%

Tenaya Therapeutics Inc EBIT to Total Assets Ratio 1 year YoY Change (%) is -38.41% for the Trailing 12 Months (TTM) ending March 31, 2024, a 25.16% change year over year. The EBIT to Total Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of total assets. It shows how efficiently a company utilizes its assets to generate earnings. A higher ratio indicates better asset utilization and profitability. It reflects the ability of a company to generate earnings from its invested assets and is useful in assessing operational efficiency and financial performance. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Tenaya Therapeutics Inc EBIT to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -0.13, a -51.32% change year over year.
Tenaya Therapeutics Inc EBIT to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.09, a -14.94% change year over year.
Tenaya Therapeutics Inc EBIT to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -0.08.

NASDAQ: TNYA

Tenaya Therapeutics Inc

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees	140
Sector	Healthcare
Industry	Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends